膛胱移行细胞癌中c—erbB—2,p53及p16蛋白的表达

目的 探讨膛胱癌组织中ｐ１６、ｃ－ｅｒｂＢ－２和ｐ５３蛋白表达与胱癌病理分级、临床分期和转移的关系。方法 应用免疫组化ＳＰ法对７５例膛胱癌组织中ｐ１６、ｐ５３及ｃ－ｅｒｂＢ－２蛋白表达进行检测。结果 ７５例膛胱癌中ｐ１６、ｐ５３及ｃ－ｅｒｂＢ－２的阳性率分别为４１．３％（３１／７５）、４４．０％（３３／７５）和４０．０％（３０／７５）,ｐ１６和ｃ－ｅｒｂＢ－２蛋白在膛胱癌中的阳性率与肿瘤中的阳性率

p16, p53 and c-erbB-2 gene expression in bladder carcinoma

OBJECTIVE: To investigate the expression of p16, p53 and c-erbB-2 proteins in bladder carcinoma and to analyze their correlation with tumor grade, clinic stage and metastasis. METHODS: Immunohistochemical method was used to detect the p16, p53 and c-erbB-2 gene expressions in 75 cases of bladder carcinoma. RESULTS: Positive rates of p16, p53 and c-erbB-2 in 75 cases of bladder cancer were 41.3%, 44.0% and 40.0%, respectively. p16 and c-erbB-2 gene expressions were related to the tumor grade and clinic stage (P < 0.05); p53 and c-erbB-2 gene expressions were related to the clinic stage and metastasis (P < 0.01). Oncogenes and/or antioncogenes altered expressions were found in 77.3% cases of bladder carcinoma, and oncogenes and/or antioncogenes with multiple altered expressions were found in 53.3% cases. CONCLUSION: The analysis of multiple oncogene and/or antioncogene is more valuable than that of single oncogene and/or antioncogene. The altered expression of oncogene c-erbB-2 and antioncogenes p16 and p53 might play a promotive role in the tumorigenesis and development of bladder tumors.